Edwards Lifesciences Corporation (EW) is currently embroiled in a
class action lawsuit with investors due to blatant
securities fraud, forcing several large holders, such as M&T Bank Corp and Nomura Asset Management, to trim their stocks. Amid this turmoil, some investors and firms like Conway Capital Management Inc., Neo Ivy Capital Management, and World Investment Advisors LLC, are taking the opportunity to augment their positions in EW, despite its underperformance against the S&P 500. The company's
Q3 2024 Earnings Call reported sturdy growth in TMTT sales. However, analysts are skeptical about
EW's returns on capital and are urging investors to be cautious. Despite these predicaments, Edwards Lifesciences remains determined for potential growth, as it outlined in its recent
Investor Conference. Certain unforeseen future matters could be
weak guidance and missed earnings expectations that led to a heavy fall in stock prices.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sat, 14 Dec 2024 10:14:30 GMT -
Rating -8
- Innovation 5
- Information 7
- Rumor -6
